MX2009002065A - Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar. - Google Patents

Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar.

Info

Publication number
MX2009002065A
MX2009002065A MX2009002065A MX2009002065A MX2009002065A MX 2009002065 A MX2009002065 A MX 2009002065A MX 2009002065 A MX2009002065 A MX 2009002065A MX 2009002065 A MX2009002065 A MX 2009002065A MX 2009002065 A MX2009002065 A MX 2009002065A
Authority
MX
Mexico
Prior art keywords
lung cancer
invasion
pharmaceutical composition
treating lung
inhibiting
Prior art date
Application number
MX2009002065A
Other languages
English (en)
Inventor
Hyo Jeong Hong
Jung-Whoi Lee
Jin Man Kim
Yeon Sung Son
Eung Suck Lee
Original Assignee
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Of Bioscience filed Critical Korea Res Inst Of Bioscience
Publication of MX2009002065A publication Critical patent/MX2009002065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se describe una composición farmacéutica para inhibir la proliferación o metástasis de células de cáncer de pulmón, que comprende una sustancia que inhibe la actividad de LICAM o que suprime la expresión de LICAM, que es una proteína que está presente en la superficie de las células de cáncer de pulmón, y un método de tratamiento utilizando la composición; los anticuerpos monoclonales de ratón, que reconocen la proteína LICAM en la superficie de la célula de SCLC y que se unen específicamente a tejidos de SCLC, o ARNsi, y oligonucleótidos antisentido o ARNsh, pueden ser útiles en el tratamiento del cáncer de pulmón inhibiendo el crecimiento, la invasión y la migración de las células de cáncer de pulmón.
MX2009002065A 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar. MX2009002065A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20060079969 2006-08-23
KR1020070084869A KR100932698B1 (ko) 2006-08-23 2007-08-23 폐암의 치료용 약제학적 조성물 및 이를 이용한 폐암의성장, 전이 억제 및 치료방법
PCT/KR2007/004045 WO2008023946A1 (en) 2006-08-23 2007-08-23 A pharmaceutical composition for treating lung cancer, a method for inhibiting growth or invasion of lung cancer and a method for treating lung cancer

Publications (1)

Publication Number Publication Date
MX2009002065A true MX2009002065A (es) 2009-06-30

Family

ID=39385312

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009002065A MX2009002065A (es) 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar.
MX2009002064A MX2009002064A (es) 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar colangiocarcinoma, un metodo para inhibir el crecimiento o invasion del colangiocarcinoma y un metodo para tratamiento de colangiocarcinoma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009002064A MX2009002064A (es) 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar colangiocarcinoma, un metodo para inhibir el crecimiento o invasion del colangiocarcinoma y un metodo para tratamiento de colangiocarcinoma.

Country Status (10)

Country Link
US (1) US8153122B2 (es)
EP (2) EP2051733A1 (es)
JP (3) JP2010501548A (es)
KR (2) KR100932698B1 (es)
CN (2) CN101605560B (es)
AU (2) AU2007288620B2 (es)
BR (2) BRPI0715844A2 (es)
CA (2) CA2661669C (es)
MX (2) MX2009002065A (es)
WO (2) WO2008023947A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661669C (en) * 2006-08-23 2017-02-14 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma
NO2631248T3 (es) 2007-06-15 2018-04-14
CN105504043B (zh) * 2008-03-17 2020-01-31 雷金纳克斯生物制药公司 改进的β胸腺素片段
KR20100060351A (ko) 2008-11-27 2010-06-07 한국생명공학연구원 Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101501736B1 (ko) * 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
JP5716257B2 (ja) * 2009-02-06 2015-05-13 国立大学法人 熊本大学 胆管癌特異的糖鎖エピトープを認識するモノクローナル抗体
KR101271964B1 (ko) * 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
TW201312117A (zh) * 2011-07-28 2013-03-16 Univ Pennsylvania 用以診斷與漿液相關之腫瘤細胞的症狀及特性的方法及試劑
KR101504039B1 (ko) 2012-11-16 2015-03-19 강원대학교산학협력단 인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
WO2015042303A1 (en) * 2013-09-18 2015-03-26 Memorial Sloan-Kettering Cancer Center Inhibiting cancer metastasis
EP3186378A1 (en) * 2014-08-27 2017-07-05 Peptimed, Inc. Anti-tumor compositions and methods
CN104894259A (zh) * 2015-06-01 2015-09-09 北京泱深生物信息技术有限公司 Tex19基因在胆管癌诊断和治疗中的应用
KR101892908B1 (ko) 2015-11-02 2018-08-29 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물
WO2017078405A1 (ko) 2015-11-02 2017-05-11 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 폐암 치료용 약학 조성물
WO2018026947A1 (en) 2016-08-02 2018-02-08 Memorial Sloan-Kettering Cancer Center Treating metastatic cancer and model systems for metastatic disease
KR20180079232A (ko) * 2016-12-30 2018-07-10 강원대학교산학협력단 L1cam 단백질에 특이적으로 결합하는 항체 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7353187B2 (ja) * 2017-06-15 2023-10-05 メモリアル スローン－ケタリング キャンサー センター 抗ｌ１－ｃａｍ抗体およびその使用
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
GB201913121D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913123D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913122D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CN111053774B (zh) * 2019-12-20 2022-10-11 厦门大学 盐酸他克林在制备治疗胆管癌的药物中的应用
CN112239505B (zh) * 2020-10-13 2022-05-20 上海良润生物医药科技有限公司 重组抗cd171八价抗体及神经来源外泌体的捕获方法
CN114657129B (zh) * 2022-04-11 2023-12-01 中山大学孙逸仙纪念医院 一种胆管癌淋巴结转移动物模型及其构建方法
CN114917348B (zh) * 2022-06-21 2023-08-04 四川大学华西医院 神经粘附因子在制备抑制和标记肝癌细胞转移的试剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872225A (en) 1992-06-26 1999-02-16 Case Western Reserve University Method for characterizing the nucleotide sequence of L1CAM and the nucleotide sequence characterized thereby
ATE377192T1 (de) 2000-07-10 2007-11-15 Deutsches Krebsforsch Diagnostisches verfahren für eierstock- und endometriumtumore basierend auf dem nachweis des l1-adhäsionsmoleküls
US20040082847A1 (en) * 2002-10-23 2004-04-29 Mcdermott Kathleen B. System and methods for identifying brain regions supporting language
US20040115206A1 (en) 2002-10-24 2004-06-17 Thomas Primiano Antibody-mediated induction of tumor cell death
JPWO2005023301A1 (ja) * 2003-09-04 2006-11-02 中外製薬株式会社 胆管癌治療剤および検出薬
EP1623995A1 (en) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
CA2661669C (en) * 2006-08-23 2017-02-14 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma

Also Published As

Publication number Publication date
CA2661669A1 (en) 2008-02-28
CN101528258A (zh) 2009-09-09
EP2054083B1 (en) 2013-11-27
AU2007288619A1 (en) 2008-02-28
EP2054083A1 (en) 2009-05-06
JP2010501548A (ja) 2010-01-21
JP2010501549A (ja) 2010-01-21
KR100931976B1 (ko) 2009-12-15
CA2661665A1 (en) 2008-02-28
CA2661669C (en) 2017-02-14
US20100196350A1 (en) 2010-08-05
CN101605560B (zh) 2013-06-26
EP2054083A4 (en) 2010-03-24
KR20080018149A (ko) 2008-02-27
WO2008023946A1 (en) 2008-02-28
JP2015007045A (ja) 2015-01-15
AU2007288620A1 (en) 2008-02-28
AU2007288620B2 (en) 2012-08-30
JP5923233B2 (ja) 2016-05-24
CN101605560A (zh) 2009-12-16
US8153122B2 (en) 2012-04-10
BRPI0715844A2 (pt) 2013-11-26
EP2051733A1 (en) 2009-04-29
KR20080018150A (ko) 2008-02-27
KR100932698B1 (ko) 2009-12-21
WO2008023947A1 (en) 2008-02-28
BRPI0715845A2 (pt) 2014-11-11
MX2009002064A (es) 2009-06-30

Similar Documents

Publication Publication Date Title
MX2009002065A (es) Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar.
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
UA99633C2 (ru) Антитело, специфически связывающееся с человеческим белком ron
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
WO2007053577A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006050026A3 (en) Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA200801732A1 (ru) Модуляторы ауроракиназы, способы их получения и их применение
TW200714289A (en) Treatment of bone disorders
WO2012005550A3 (ko) 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
WO2004005457A3 (en) Tfc/ beta-catenin regulated genes for treating cancer
EA201690994A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
EP1864134A4 (en) METHODS OF TREATING OR PREVENTING HORMONE-RESISTANT PROSTATE CANCER USING SMALL INTERFERING RNA SPECIFIC TO PROTOCADHERINE-PC, OR OTHER INHIBITORS OF PROTOCADHERINE-PC EXPRESSION OR ACTIVITY
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
IL179513A0 (en) Methods of treating type i diabetes by blocking vegf - mediated activity
DE602007012743D1 (de) Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs
EP1859806A4 (en) METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS, PLATED CELL CARCINOMA AND / OR PARACERATOSIS BY INHIBITION OF EXPRESSION OF PLATE CELL CARCINOMA RELEVANT ANTIGEN
WO2013104050A3 (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
WO2007103876A3 (en) Cancer therapeutic